Johnson & Johnson’s Consumer Segment: 4Q17 Estimates

Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. The segment is expected to have positive growth in revenues for 4Q17.

The above chart compares revenues for the Consumer segment over the last eight quarters.

The oral care franchise is expected to report a decline in revenues in 4Q17 due to weaker sales in the US markets. A strong expected performance of Total Care Zero and whitening products is expected to offset the decline in revenues.

Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products. It’s expected to be partially offset by lower sales from EMEA (Europe, the Middle East, and Africa) markets.

The over-the-counter franchise is expected to report growth in revenues in 4Q17 due to strong sales of analgesics and Tylenol and the inclusion of Rhinocort, partially offset by lower sales of Zyrtec.

The wound care franchise is expected to report growth in revenues in 4Q17 due to new product launches in international markets, partially offset by lower sales in US markets.

The baby care franchise is expected to report a decline in revenues in 4Q17 following lower sales due to competition.

The women’s health franchise is expected to report growth in revenues in 4Q17 following new product launches, partially offset by lower sales in US markets.

The VanEck Vectors Pharmaceutical ETF (PPH) holds 4.6% of its total investments in Johnson & Johnson (JNJ), 4.7% in Pfizer (PFE), 4.9% in GlaxoSmithKline (GSK), and 4.8% in AstraZeneca (AZN).